Regulation & Compliance

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.

New AI tech lets car dealers profile you on arrival. It promises efficiency, but at what cost to your privacy and power in the negotiation?

BingX aims to democratize crypto trading with a new partner, but our investigation reveals Trade4Me is unregulated and flagged for potential fraud.

CityHealth's 2025 report shows local policy is potent medicine. Discover how cities like Chicago are using data to tackle health, from housing to greenspace.

Amid rapid expansion and heightened regulatory scrutiny, PACS Group hires new compliance and HR chiefs to fortify its operational foundation for the future.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

With its finances in distress, Netcapital bets its future on blockchain and a new CEO. Can a turnaround specialist navigate the crypto frontier?

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

Lifestyle experts are shaping your holiday shopping. We dissect the strategy behind curated gift guides, influencer endorsements, and the media firms driving them.

A new Canada-Germany digital alliance promises AI and quantum breakthroughs. But can this pact move from policy to patients and transform Canadian health?

With a new SVP of Growth, John Henry, RestorixHealth signals an aggressive push in the booming wound care market, navigating tech shifts and regulatory hurdles.

Enterprises are shifting from AI that gives answers to AI that takes action. A new forecast reveals how autonomous agents will redefine work by 2026.

Sana Biotech’s new data shows it can edit stem cells directly in the body, a potential game-changer for blood disorders and a challenge to current therapies.

As the aging U.S. grid strains under explosive demand, industrial leaders are turning to microgrids for energy independence and financial stability.

A new investment narrative targets 'essential' sectors. A deep dive reveals a complex mix of real strategy, verifiable progress, and pure promotion.

Quantum computers will soon break today's encryption. A new security standard is here, but are automakers moving fast enough to prevent a systemic failure?

A new partnership aims to revolutionize public safety with faster, smarter security screening. But can advanced AI balance security with personal privacy?

Enterprises lose up to 9% of revenue from missed contract obligations. New AI tools are turning static legal documents into actionable intelligence.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.